BioCentury | Aug 19, 2020
Product Development

Launch of generic Tecfidera puts more pressure on Biogen’s pipeline

...Stock of Biogen’s Pipeline”; “Billion-Dollar Biogen Deal”). Mylan already markets generic formulations of MS drug Copaxone glatiramer acetate...
...the first FDA-approved generic to Teva’s thrice-weekly formulation in 2017 (see “FDA Approves Mylan’s Generic Copaxone”).On...
...District of Massachusetts alleging that Teva paid kickbacks in the form of co-pay subsidies for Copaxone...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...of less than $20 million from partner Sandoz for Glatopa glatiramer acetate, its generic formulation of Copaxone...
BioCentury | Dec 16, 2019
Financial News

Immuneering to bolster cancer pipeline, expand services unit with $17M series A

...in-house pipeline in parallel. Zeskind said Immuneering's bioinformatics services unit has performed analyses of Copaxone glatiramer acetate...
BioCentury | Feb 13, 2019
Company News

Teva down after predicting a 'trough' year ahead

...year as Teva faces increasing generic erosion to sales of its multiple sclerosis drug Copaxone glatiramer acetate...
...expecting EPS of $2.82 on $17.89 billion in revenues. The pace of generic erosion to Copaxone...
...of $18.82 billion. Consensus figures provided by FactSet. Chris Lieu Ajovy, fremanezumab-vfrm (TEV-48125, lbr-101, rn-307) Austedo, deutetrabenazine (SD-809) Copaxone, glatiramer acetate ProAir...
BioCentury | Dec 7, 2018
Tools & Techniques

Filaments line up as MS biomarker

...with Tysabri natalizumab or Tecfidera dimethyl fumarate from Biogen, Campath-1H alemtuzumab from Sanofi and Copaxone glatiramer acetate...
BioCentury | Oct 5, 2018
Company News

Momenta cutting biosimilar programs, headcount

...sclerosis drug Copaxone glatiramer acetate, dropped 64% compared with 1H17 after Mylan launched its own generic Copaxone...
BioCentury | Oct 1, 2018
Company News

Momenta cutting biosimilar programs, headcount

...sclerosis drug Copaxone glatiramer acetate, dropped 64% compared with 1H17 after Mylan launched its own biosimilar Copaxone...
BioCentury | Apr 20, 2018
Company News

Mylan gets worldwide rights to glatiramer acetate depot

...worldwide rights to develop and commercialize glatiramer acetate depot (GA Depot). The long-acting depot formulation of glatiramer acetate...
...disclose financial terms. Mapi-Pharma Ltd., Ness Ziona, Israel Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Neurology Alicia Parker Glatiramer acetate...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...approves thrice-weekly 40 mg/mL Glatopa glatiramer acetate injection as a generic version of multiple sclerosis drug Copaxone...
BioCentury | Mar 30, 2018
Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

...used in the control arm included Tysabri natalizumab, Tecfidera dimethyl fumarate, Gilenya fingolimod, interferons, Copaxone glatiramer acetate...
...Status Scale (EDSS) Status: Phase III data Milestone: NA Jennie Walters Avonex, interferon beta-1a Betaferon, Betaseron, interferon beta-1b Copaxone, glatiramer acetate Gilenya...
Items per page:
1 - 10 of 412